## **HEALEY ALS Platform Trial**

#### Weekly Q&A – June 30, 2022





Muscular

Dystrophy Association



























**M**2



SALSA

**TAMBOURINE** 



The Arthur M. Blank FAMILY FOUNDATION





## **Guest Speaker**

#### Gale Kittle, RN, MPH Director, Outcome Measurements Training Barrow Neurological Institute, Phoenix AZ



## **Barrow Neurological Institute Clinical Research Organization**

• Outcomes and Clinical Monitoring team specialized in Neurological Disorders.





**BNI** Outcomes Center: Phoenix, AZ

#### **Barrow** Neurological Institute



Organization


















# Trained/certified more than 1,400 evaluators in 27 countries



Barrow Neurological Institute



Clinical Research Organization

## Core Outcomes Team







Gale Kittle, RN, MPH Director/Trainer

Jenny Hamilton, BA, CCRC Project Manager Marlee Lovett, BS Research Assistant Jasi Torres, BS Research Assistant



## Platform Trial Outcome Measures

#### ALSFRS-R



### Vital Capacity




#### HHD



(Hand-held Dynamometry)

#### Home Spirometry





## Training and Certification

#### Training

- Investigator Meetings: In-person or virtual
- Self-accessed webinar on training portal
- Real life or video practice/demonstrations

#### Certification

- Perform practice assessments
- Must meet specific criteria for reliability requirement
- Retests and one-on-one training if required
- Regular certificate renewal (annually or every two years)








**Clinical Research** 

Organization



### The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



## Enrollment Updates (as of June 30, 2022)

• 83 individuals have signed informed consent

• 55 individuals have been randomized within Regimen E


Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

**Every research participant, whether on the active drug or placebo, plays a critical role** in making the hope of finding a cure for ALS a reality

## 38 Sites Currently Activated for Regimen E



#### (as of 6/30/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

- Lehigh Valley Health Network
- 🗹 Mass General Hospital
- University of Kansas
- University of Maryland
- 🗹 California Pacific Medical Center
- 🗹 Northwestern University
- Virginia Commonwealth University
- University of Nebraska
- ☑ Washington University
- Wake Forest University
- Hospital for Special Care
- Saint Alphonsus Regional
- University of Massachusetts
- 🗹 Duke University
- Sarrow Neurological Institute
- Georgetown University
- Texas Neurology
- Beth Israel Deaconess Medical Center
- SUNY Upstate
- 🗹 Spectrum Health
- Menry Ford Hospital
- 🗹 Essentia Health
- University of Southern California
- 🗹 University of South Florida
- 🖾 University of Colorado
- Providence Brain and Spine
- 🗹 University of Minnesota
- 🗹 🛛 Loma Linda University
- 🗹 University of Iowa
- Swedish Medical Center
- Ohio State University
- University of Cincinnati
- Thomas Jefferson University

#### UC San Francisco

- 🗹 Mayo Rochester
- University of Washington
- Vanderbilt University





Site Map & Contacts:



## Patient Navigation Central resource for people living with ALS

E-mail:healeyalsplatform@mgh.harvard.edu



Phone: 833-425-8257 (HALT ALS)

Weekly webinar registration:

**Catherine Small** 





https://bit.ly/3r6Nd2L

ALS Link sign-up:



https://bit.ly/3o2Ds3m

#### **Upcoming Guest Speakers:**

July 7<sup>th</sup>- James Berry, MD, MPH (Discussion about Biomarkers) July 14<sup>th</sup>- Eufrosina Young, MD (Investigator at SUNY Upstate, New York)

Allison Bulat